Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 3

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 32INDUSTRY 7OTHER_GOV 3NIH 1

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 3Gastrointestinal 2Thoracic 1Lymphoid 1

Conditions

Melanoma 3Polyps 1Lymphoma, Follicular 1Liver Neoplasms 1Huntington Disease 1Carcinoma, Non-Small-Cell Lung 1Adenomatous Polyposis Coli 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Docosahexaenoic Acids × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00422877 2025-10-16

Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract

American Regent, Inc.

Phase 2 Terminated
13 enrolled
Gastrointestinal

Liver Neoplasms

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00087776 2025-07-23

Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma

American Regent, Inc.

Phase 3 Terminated
393 enrolled
Dermatologic

Melanoma

NCT03806426 2024-04-25

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

S.L.A. Pharma AG

Phase 3 Unknown
204 enrolled
Gastrointestinal

Adenomatous Polyposis Coli, Polyps

NCT00146211 2007-12-27

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Amarin Neuroscience Ltd

Phase 3 Completed
300 enrolled
Lymphoid

Huntington Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡